Categories: HealthcareNewsSeniors

InnovAge to Announce Fiscal Second Quarter 2023 Financial Results and Host Conference Call Tuesday, February 7, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

DENVER, Jan. 24, 2023 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV) will release its 2023 fiscal second quarter financial results on Tuesday, February 7, 2023, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T.

Conference Call Details
A live audio webcast of the call will be available on the Company’s website, https://investor.innovage.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for a limited time. To access the call by phone, please go to this link (registration link), for dialing instructions and a unique access pin. We encourage participants to dial into the call fifteen minutes ahead of the scheduled start time.

About InnovAge
InnovAge is a market leader in managing the care of high-cost, dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care its participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers, and government payors — “win.” As of September 30, 2022, InnovAge served approximately 6,540 participants across 18 centers in five states. https://www.innovage.com/.

Investor Contact:
Ryan Kubota
rkubota@myinnovage.com

Media Contact:
Sarah Rasmussen, APR
srasmussen@myinnovage.com

Staff

Recent Posts

Marius Pharmaceuticals Receives Sixth U.S. Patent Allowance for KYZATREX® (testosterone undecanoate) CIII Capsules Extending Coverage to 2040

RALEIGH, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on…

2 hours ago

Olympia Pharmaceuticals Secures $637,000 Workforce Training Grant to Boost Job Creation in Orlando

The funding will train 100 new employees at Wesley Pharmaceuticals, supporting local talent and healthcare…

2 hours ago

Immunotherapeutic Targets for Recurrent Medulloblastoma Receives $85K Grant from Brain Cancer Canada

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is proud to award $85,000…

2 hours ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect…

2 hours ago

PacBio to Present at Upcoming Investor Conferences

MENLO PARK, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer…

2 hours ago

Flare Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology…

2 hours ago